Antitumorigenic Effects of ZAKβ, an Alternative Splicing Isoform of ZAK

10.4077/CJP.2018.BAG528

Jin-Sun Lee；Yuh-Yih Lin；Tsu-Shing Wang；Jer-Yuh Liu；Wei-Wen Lin；Jaw-Ji Yang

alternative splicing ； β-catenin ； CREB ； NFκB ； ZAKα ； ZAKβ

The Chinese Journal of Physiology

61卷1期（2018 / 02 / 28）

25 - 34

英文

Sterile alpha motif (SAM)- and leucine-zipper-containing kinase (ZAK) plays a role in the regulation of cell cycle progression and oncogenic transformation. The ZAK gene generates two transcript variants, ZAKα and ZAKβ, through alternative splicing. In this study, we identified that ZAKα proteins were upregulated in tumor tissues, whereas ZAKβ proteins were mostly expressed in corresponding normal tissues. The ectopically expressed ZAKβ proteins in cancer cells inhibited cancer cell proliferation as well as anchorage-independent growth. The ZAKβ:ZAKα protein ratio played a role in the regulation of the cyclic adenosine monophosphate (cAMP) signaling pathway, whereas high ZAKβ protein levels led to the activation of cAMP response element binding protein 1 (CREB1) and exerted antitumor properties. Overexpression of ZAKβ or CREB1 cDNAs in cancer cells inhibited anchorage-independent growth and also reduced the levels of cyclooxygenase 2 (Cox2) and β-catenin proteins. Cancer cells treated with doxorubicin (Doxo) resulted in the switching from the expression of ZAKα to ZAKβ and also inhibited cancer cell growth in soft agar, demonstrating that pharmacological drugs could be used to manipulate endogenous reprogramming splicing events and resulting in the activation of endogenous antitumorigenic properties. We showed that the two ZAK transcript variants, ZAKα and ZAKβ, had opposite biological functions in the regulation of tumor cell proliferation in that ZAKβ had powerful antitumor properties and that ZAKα could promote tumor growth.

1. Lee, J.S.,Wang, T.S.,Lin, M.C.,Lin, W.W.,Yang, J.J.(2017).Inhibition of curcumin on ZAKα activity resultant in apoptosis and anchorage-independent growth in cancer cells.Chinese J. Physiol.,60,267-274.
   連結：
2. Chadee, D.N.(2012).Involvement of mixed lineage kinase 3 in cancer.Can. J. Physiol. Pharmacol.,91,268-274.
3. Chang, J.T.(2004).An economic and efficient method of RNAi vector constructions.Anal. Biochem.,334,199-200.
4. Cho, Y.Y.,Bode, A.M.,Mizuno, H.,Choi, B.Y.,Choi, H.S.,Dong, Z.(2004).A novel role for mixed-lineage kinase-like mitogenactivated protein triple kinase α in neoplastic cell transformation and tumor development.Cancer Res.,64,3855-3864.
5. Craene, B.D.,Berx, G.(2013).Regulatory networks defining EMT during cancer initiation and progression.Nat. Rev. Cancer,13,97-110.
6. Craige, S.M.,Reif, M.M.,Kant, S.(2016).Mixed - lineage protein kinases (MLKs) in inflammation, metabolism, and other disease states.Biochim. Biophys. Acta,1862,1581-1586.
7. Firestein, R.,Bass, A.J.,Kim, S.Y.,Dunn, I.F.,Silver, S.J.,Guney, I.,Freed, E.,Ligon, A.H.,Vena, N.,Ogino, S.,Chheda, M.G.,Tamayo, P.,Finn, S.,Shrestha, Y.,Boehm, J.S.,Jain, S.,Bojarski, E.,Mermel, C.,Barretina, J.,Chan, J.A.,Baselga, J.,Tabernero, J.,Root, D.E.,Fuchs, C.S.,Loda, M.,Shivdasani, R.A.,Meyerson, M.,Hahn, W.C.(2008).CDK8 is a colorectal cancer oncogene that regulates [beta]-catenin activity.Nature,455,547-551.
8. Fuchs, S.Y.,Ougolkov, A.V.,Spiegelman, V.S.,Minamoto, T.(2005).Oncogenic β-catenin signaling networks in colorectal cancer.Cell Cycle,4,1522-1539.
9. Gallo, K.A.,Johnson, G.L.(2002).Mixed-lineage kinase control of JNK and p38 MAPK pathways.Nat. Rev. Mol. Cell Biol.,3,663-672.
10. Garraway, L.A.,Lander, E.S.(2013).Lessons from the cancer genome.Cell,153,17-37.
11. Gotoh, I.,Adachi, M.,Nishida, E.(2001).Identification and characterization of a novel MAP kinase kinase kinase, MLTK.J. Biol. Chem.,276,4276-4286.
12. Hanahan, D.,Weinberg, R.A.(2011).Hallmarks of cancer: the next generation.Cell,144,646-674.
13. Hanahan, D.,Weinberg, R.A.(2000).The hallmarks of cancer.Cell,100,57-70.
14. Harper, S.J.,Bates, D.O.(2008).VEGF-A splicing: the key to anti-angiogenic therapeutics?.Nat. Rev. Cancer,8,880-887.
15. Huang, C.Y.,Yang, L.C.,Liu, K.Y.,Chang, I.C.,Liao, P.H.,Chou, J.,Chou, M.Y.,Lin, W.W.,Yang, J.J.(2009).ZAK negatively regulates RhoGDIbeta-induced Rac1-mediated hypertrophic growth and cell migration.J. Biomed. Sci.,16,56.
16. Huang, C.Y.,Yang, L.C.,Liu, K.Y.,Liao, P.H.,Chou, J.,Chou, M.Y.,Lin, W.W.,Yang, J.J.(2009).RhoGDIbeta-induced hypertrophic growth in H9c2 cells is negatively regulated by ZAK.J. Biomed. Sci.,16,11.
17. Liu, J.,McCleland, M.,Stawiski, E.W.,Gnad, F.,Mayba, O.,Haverty, P.M.,Durinck, S.,Chen, Y.J.,Klijn, C.,Jhunjhunwala, S.,Lawrence, M.,Liu, H.,Wan, Y.,Chopra, V.,Yaylaoglu, M.B.,Yuan, W.,Ha, C.,Gilbert, H.N.,Reeder, J.,Pau, G.,Stinson, J.,Stern, H.M.,Manning, G.,Wu, T.D.,Neve, R.M.,de Sauvage, F.J.,Modrusan, Z.,Seshagiri, S.,Firestein, R.,Zhang, Z.(2014).Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.Nat. Commun.,5,3830.
18. Liu, T.C.,Huang, C.J.,Chu, Y.C.,Wei, C.C.,Chou, C.C.,Chou, M.Y.,Chou, C.K.,Yang, J.J.(2000).Cloning and expression of ZAK, a mixed lineage kinase-like protein containing a leucine-zipper and a sterile-alpha motif.Biochem. Biophys. Res. Commun.,274,811-816.
19. Nieto, M.A.(2011).The ins and outs of the epithelial to mesenchymal transition in health and disease.Annu. Rev. Cell Dev. Biol.,27,347-376.
20. Polakis, P.(2007).The many ways of Wnt in cancer.Curr. Opin. Genet. Dev.,17,45-51.
21. Polakis, P.(2000).Wnt signaling and cancer.Genes Dev.,14,1837-1851.
22. Rana, A.,Rana, B.,Mishra, R.,Sondarva, G.,Rangasamy, V.,Das, S.,Viswakarma, N.,Kanthasamy, A.(2013).Mixed lineage kinase-c-Jun N-terminal kinase axis: a potential therapeutic target in cancer.Genes Cancer,4,334-341.
23. Rey, C.,Faustin, B.,Mahouche, I.,Ruggieri, R.,Brulard, C.,Ichas, F.,Soubeyran, I.,Lartigue, L.,De Giorgi, F.(2016).The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.Oncogene,35,3190-3200.
24. Shchelkunova, A.,Ermolinsky, B.,Boyle, M.,Mendez, I.,Lehker, M.,Martirosyan, K.S.,Kazansky, A.V.(2013).Tuning of alternative splicing - switch from proto-oncogene to tumor suppressor.Int. J. Biol. Sci.,9,45-54.
25. Sobolewski, C.,Cerella, C.,Dicato, M.,Ghibelli, L.,Diederich, M.(2010).The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.Int. J. Cell Biol.,2010,215158.
26. Takemura, G.,Fujiwara, H.(2007).Doxorubicin-induced cardiomyopathy.Prog. Cardiovasc. Dis.,49,330-352.
27. Venables, J.P.(2006).Unbalanced alternative splicing and its significance in cancer.BioEssays,28,378-386.
28. Wagner, E.F.,Nebreda, A.R.(2009).Signal integration by JNK and p38 MAPK pathways in cancer development.Nat. Rev. Cancer,9,537-549.
29. Yang, J.J.(2002).Mixed lineage kinase ZAK utilizing MKK7 and not MKK4 to activate the c-Jun N-terminal kinase and playing a role in the cell arrest.Biochem. Biophys. Res. Commun.,297,105-110.
30. Yang, J.J.,Krauss, R.S.(1997).Extracellular ATP induces anchorage-independent expression of cyclin A and rescues the transformed phenotype of a ras-resistant mutant cell line.J. Biol. Chem.,272,3103-3108.